MCID: FNC002
MIFTS: 37

Functional Diarrhea malady

Categories: Gastrointestinal diseases

Aliases & Classifications for Functional Diarrhea

Aliases & Descriptions for Functional Diarrhea:

Name: Functional Diarrhea 12 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:11371
ICD10 33 K59.1
ICD9CM 35 564.5
SNOMED-CT 64 47812002
UMLS 69 C0156173

Summaries for Functional Diarrhea

MalaCards based summary : Functional Diarrhea is related to mixed lacrimal gland cancer and simultanagnosia, and has symptoms including constipation, diarrhea and vomiting following gastrointestinal surgery. An important gene associated with Functional Diarrhea is ITM2B (Integral Membrane Protein 2B), and among its related pathways/superpathways are Serotonergic synapse and Farnesoid X Receptor Pathway. The drugs Aspirin and Ticlopidine have been mentioned in the context of this disorder. Affiliated tissues include colon, and related phenotypes are behavior/neurological and adipose tissue

Related Diseases for Functional Diarrhea

Diseases related to Functional Diarrhea via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
id Related Disease Score Top Affiliating Genes
1 mixed lacrimal gland cancer 10.2 HTR3A HTR7 TAC1
2 simultanagnosia 10.2 HTR7 NTS TAC1
3 cervical carcinosarcoma 10.2 HTR7 NTS TAC1
4 central nervous system vasculitis 10.2 DNTT TAC1
5 scrotum melanoma 10.2 ATP12A ATP4A
6 congenital diaphragmatic hernia 10.1 ATP12A ATP4A
7 secondary syphilis 10.1 ATP12A ATP4A
8 brain edema 10.1 ATP12A ATP4A
9 intracranial hypertension 10.1 ATP12A ATP4A
10 staphyloenterotoxemia 10.1 ATP12A ATP4A
11 microphthalmia, syndromic 12 10.1 ATP12A ATP4A
12 ceruminoma 10.1 ATP12A ATP4A
13 lateral sinus thrombosis 10.1 ATP12A ATP4A HTR3A
14 amyotrophic lateral sclerosis type 10 10.1 ATP12A ATP4A
15 nutritional optic neuropathy 10.1 GHRL HTR4
16 oculogyric crisis 10.1 ATP12A ATP4A TAC1
17 tuberculous peritonitis 10.1 HTR3A HTR4 HTR7 TAC1
18 autism spectrum disorder 10.0 GHRL HTR7 TAC1
19 sweat gland cancer 10.0 HTR3A HTR4 NTS TAC1
20 diarrhea 10.0
21 uterine ligament clear cell adenocarcinoma 10.0 GHRL HTR4 TAC1
22 abnormal pupillary function 10.0 ATP12A ATP4A HTR3A HTR7
23 acute gonococcal cervicitis 9.9 ATP12A ATP4A GHRL TAC1
24 spinal muscular atrophy with progressive myoclonic epilepsy 9.9 ATP12A ATP4A RAB11A
25 childhood intracortical osteosarcoma 9.9 ATP12A ATP4A GHRL HTR4
26 scleral staphyloma 9.9 ATP12A ATP4A GHRL HTR3A HTR7
27 childhood malignant hemangiopericytoma 9.9 ATP12A ATP4A GHRL HTR4
28 deafness, autosomal recessive 20 9.9 ATP4A HTR3A HTR4 HTR7 ITM2B TAC1
29 irritable bowel syndrome 9.8
30 in situ pulmonary adenocarcinoma 9.8 CDH1 MMP1 TNC
31 constipation 9.5
32 dyspepsia 9.5
33 cerebritis 9.5
34 gnathomiasis 7.8 ATP12A ATP4A CDH1 DNTT FGF19 GHRL

Comorbidity relations with Functional Diarrhea via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease

Graphical network of the top 20 diseases related to Functional Diarrhea:



Diseases related to Functional Diarrhea

Symptoms & Phenotypes for Functional Diarrhea

UMLS symptoms related to Functional Diarrhea:


constipation, diarrhea, vomiting following gastrointestinal surgery

MGI Mouse Phenotypes related to Functional Diarrhea:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.9 TAC1 TNC TOR1A GHRL HTR3A HTR4
2 adipose tissue MP:0005375 9.73 GHRL GPBAR1 HTR4 NR1H4 NTS PIK3C2A
3 growth/size/body region MP:0005378 9.7 ATP12A CDH1 FGF19 GPBAR1 HTR3A HTR4
4 homeostasis/metabolism MP:0005376 9.53 ATP12A ATP4A CDH1 DNTT FGF19 GHRL

Drugs & Therapeutics for Functional Diarrhea

Drugs for Functional Diarrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 486)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
2
Ticlopidine Approved Phase 4 55142-85-3 5472
3
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
4
Cyclosporine Approved, Investigational, Vet_approved Phase 4,Phase 2 79217-60-0, 59865-13-3 5284373 6435893
5
Everolimus Approved Phase 4 159351-69-6 6442177
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 83-43-2 6741
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-24-8 5755
11
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
12
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
13
Loperamide Approved Phase 4,Phase 2,Phase 3,Phase 1 53179-11-6 3955
14
Donepezil Approved Phase 4 120014-06-4 3152
15
Dopamine Approved Phase 4,Phase 1 51-61-6, 62-31-7 681
16
Galantamine Approved Phase 4 357-70-0 9651 908828, 9651
17
Memantine Approved, Investigational Phase 4 19982-08-2 4054
18
Rivastigmine Approved, Investigational Phase 4,Phase 1 123441-03-2 77991
19
Paroxetine Approved, Investigational Phase 4,Phase 2 61869-08-7 43815
20
Ondansetron Approved Phase 4,Phase 2 99614-02-5 4595
21 Ramosetron Approved Phase 4,Phase 3,Phase 2 132036-88-5
22
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
23
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
24
Lenograstim Approved Phase 4 135968-09-1
25
Certolizumab pegol Approved Phase 4 428863-50-7
26
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
27
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3 242138-07-4
28
Praziquantel Approved, Vet_approved Phase 4 55268-74-1 4891
29
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
30
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
31
Budesonide Approved Phase 4,Phase 3 51333-22-3 63006 5281004
32
Acetylcholine Approved Phase 4 51-84-3 187
33
Eluxadoline Approved Phase 4 864821-90-9
34
Naloxegol Approved Phase 4 854601-70-0
35
lanreotide Approved Phase 4 108736-35-2
36
Somatostatin Approved Phase 4 38916-34-6, 51110-01-1 53481605
37
rituximab Approved Phase 4 174722-31-7 10201696
38
Clopidogrel Approved, Nutraceutical Phase 4 120202-66-6, 113665-84-2 60606
39
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
40
Choline Approved, Nutraceutical Phase 4 62-49-7 305
41
Creatine Approved, Nutraceutical Phase 4 57-00-1 586
42
Genistein Investigational Phase 4 446-72-0 5280961
43
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3 114977-28-5 148124 9877265
44 Antihypertensive Agents Phase 4,Phase 3,Phase 2
45 Hypoglycemic Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Cholinergic Agents Phase 4,Phase 1,Early Phase 1
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Sulfalene Phase 4,Phase 3,Phase 1,Phase 2
49 Hormone Antagonists Phase 4,Phase 3,Phase 2
50 Hormones Phase 4,Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 376)
id Name Status NCT ID Phase
1 Saccharomyces Boulardii in Diarrhea Dominant Irritable Bowel Syndrome Unknown status NCT00543478 Phase 4
2 Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) Unknown status NCT01208714 Phase 4
3 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4
4 Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Unknown status NCT01667627 Phase 4
5 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4
6 The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS) Unknown status NCT01779765 Phase 4
7 Strategy to Improve Adherence of Roflumilast Unknown status NCT02018432 Phase 4
8 Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Unknown status NCT02328963 Phase 4
9 Mode of Action of Moviprep Completed NCT01622972 Phase 4
10 Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment Completed NCT00234637 Phase 4
11 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4
12 A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD) Completed NCT02275052 Phase 4
13 Mesalazine for the Treatment of Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D) Completed NCT01316718 Phase 4
14 Study to Assess the Effect Of Alosetron On Mucosal Blood Flow Completed NCT00370032 Phase 4
15 Ondansetron for the Treatment of IBS With Diarrhoea (IBS-D) Completed NCT00745004 Phase 4
16 A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients Completed NCT01225237 Phase 4
17 A Preliminary Study to Explore Clinical Endpoints in Patients (Male) With Diarrhea-predominant Irritable Bowel Syndrome Completed NCT00918411 Phase 4
18 Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS Completed NCT00142987 Phase 4
19 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids Completed NCT02111603 Phase 4
20 Airway Hyper-responsiveness Study In Asthma Using Salmeterol/Fluticasone Propionate Combination Product Completed NCT00291382 Phase 4
21 Optimal Amount of Zinc to Include in a Lipid-based Nutrient Supplement (LNS) Completed NCT00944281 Phase 4
22 Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome Completed NCT02026518 Phase 4
23 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4
24 Dosing Flexibility Study in Patients With Rheumatoid Arthritis Completed NCT00580840 Phase 4
25 Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma Completed NCT00264849 Phase 4
26 Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome Completed NCT01886781 Phase 4
27 Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial Completed NCT00779493 Phase 4
28 Evaluation of Praziquantel Dosage for Treatment of Schistosomiasis in Brazil Completed NCT00403611 Phase 4
29 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders Recruiting NCT01098383 Phase 4
30 Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use Recruiting NCT02959983 Phase 4
31 Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance Recruiting NCT02728063 Phase 4
32 Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients Recruiting NCT02946580 Phase 4
33 The Effect of a Cash Transfer Program on Household Welfare and Child Nutritional Status in Mali Recruiting NCT02858011 Phase 4
34 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
35 Study of Rituximab to Treat Chronic Renal Transplant Rejection Active, not recruiting NCT00476164 Phase 4
36 An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Active, not recruiting NCT02590432 Phase 4
37 Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children Not yet recruiting NCT02765217 Phase 4
38 A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Not yet recruiting NCT03034915 Phase 4
39 Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility Not yet recruiting NCT03104998 Phase 4
40 Probiotics in Newly Recognized Type 1 Diabetes Not yet recruiting NCT03032354 Phase 4
41 Trial of Calcineurin Inhibitor-Sparing Immunosuppression Regimen in Pediatric Liver Transplantation Terminated NCT00656266 Phase 4
42 Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma Terminated NCT01070888 Phase 4
43 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4
44 Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse Terminated NCT01092624 Phase 4
45 Prednisone Withdrawal Versus Prednisone Maintenance After Kidney Transplant Terminated NCT00596947 Phase 4
46 Enteric Coated Myfortic for Liver Transplant Recipients Withdrawn NCT00167492 Phase 4
47 Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome Withdrawn NCT02190526 Phase 4
48 Imodium Syrup Versus Imodium Tablets for Faecal Incontinence Withdrawn NCT00933465 Phase 4
49 Multistrain Probiotic for Functional Constipation Unknown status NCT01618617 Phase 2, Phase 3
50 A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome Unknown status NCT02179580 Phase 2, Phase 3

Search NIH Clinical Center for Functional Diarrhea

Genetic Tests for Functional Diarrhea

Anatomical Context for Functional Diarrhea

MalaCards organs/tissues related to Functional Diarrhea:

39
Colon

Publications for Functional Diarrhea

Articles related to Functional Diarrhea:

(show all 14)
id Title Authors Year
1
Electroacupuncture for patients with diarrhea-predominant irritable bowel syndrome or functional diarrhea: A randomized controlled trial. ( 27310980 )
2016
2
Influence of acupuncture stimulation on cerebral network in functional diarrhea. ( 24459533 )
2013
3
Epidemiology of functional diarrhea and comparison with diarrhea-predominant irritable bowel syndrome: a population-based survey in China. ( 22937091 )
2012
4
Functional diarrhea. ( 22917168 )
2012
5
Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. ( 17549631 )
2008
6
Treatment of functional diarrhea. ( 16836952 )
2006
7
Functional diarrhea. ( 16168232 )
2005
8
Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. ( 11686387 )
2001
9
Inhibition of gastric secretion relieves diarrhea and postprandial urgency associated with irritable bowel syndrome or functional diarrhea. ( 10505731 )
1999
10
Rapid gastric emptying in patients with functional diarrhea. ( 9121178 )
1997
11
Colonic motility and functional diarrhea. ( 1622483 )
1992
12
Effect of eating on colonic motility and transit in patients with functional diarrhea. Simultaneous scintigraphic and manometric evaluations. ( 1936800 )
1991
13
Functional diarrhea: an analysis of the clinical and roentgen manifestations. ( 13397691 )
1956
14
Alterations in colonic function in man under stress; hypomotility of the sigmoid colon, and its relationship to the mechanism of functional diarrhea. ( 15421433 )
1950

Variations for Functional Diarrhea

Expression for Functional Diarrhea

Search GEO for disease gene expression data for Functional Diarrhea.

Pathways for Functional Diarrhea

Pathways related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.38 HTR3A HTR4 HTR7
2 10.6 FGF19 NR1H4
3 10.54 HTR4 HTR7
4 10.25 HTR3A HTR4 HTR7
5 10.21 CDH1 TNC

GO Terms for Functional Diarrhea

Cellular components related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.26 GHRL HTR3A RAB11A TAC1
2 transport vesicle GO:0030133 8.8 NTS RAB11A TOR1A

Biological processes related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.16 ATP12A ATP4A
2 negative regulation of bile acid biosynthetic process GO:0070858 8.96 FGF19 NR1H4
3 neuron projection development GO:0031175 8.92 CDH1 RAB11A TNC TOR1A

Molecular functions related to Functional Diarrhea according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 serotonin binding GO:0051378 9.32 HTR3A HTR7
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP12A ATP4A
3 hydrogen:potassium-exchanging ATPase activity GO:0008900 9.16 ATP12A ATP4A
4 G-protein coupled serotonin receptor activity GO:0004993 9.13 HTR3A HTR4 HTR7
5 bile acid receptor activity GO:0038181 8.62 GPBAR1 NR1H4

Sources for Functional Diarrhea

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....